OQS
ESPR icon

Occudo Quantitative Strategies’s Esperion Therapeutics ESPR Stock Holding History

Occudo Quantitative Strategies’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-66,652
Closed -$447K – 1088
2022
Q3 		$447K Buy
66,652
+14,823
+29% +$102K 0.03% 702
2022
Q2 		$330K Sell
51,829
-65,586
-56% -$372K 0.03% 762
2022
Q1 		$545K Buy
117,415
+66,343
+130% +$285K 0.05% 614
2021
Q4 		$255K Buy
+51,072
New +$409K 0.02% 819
2021
Q3 		– Sell
-10,583
Closed -$224K – 1046
2021
Q2 		$224K Buy
+10,583
New +$255K 0.03% 701
2021
Q1 		– Sell
-14,520
Closed -$378K – 803
2020
Q4 		$378K Buy
+14,520
New +$435K 0.12% 342

Other funds holding ESPR

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Occudo Quantitative Strategies's ESPR Position: Q4 2022 in Review

Occudo Quantitative Strategies sold out of Esperion Therapeutics (ESPR) in Q4 2022, closing a stake of 66,652 shares — an estimated $447K sold.

Occudo Quantitative Strategies first reported a position in ESPR in Q4 2020 and held it in 6 quarters. The position peaked at $545K in Q1 2022. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2022.

  • Occudo Quantitative Strategies reported no remaining Esperion Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 66,652 Esperion Therapeutics shares in Q4 2022, an estimated $447K.
  • Occudo Quantitative Strategies first reported a position in Esperion Therapeutics in Q4 2020 and held it in 6 quarters.
  • Occudo Quantitative Strategies's Esperion Therapeutics position peaked at $545K in Q1 2022.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.